Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

Mingxue Fan; Minghao Li; Lipeng Gao; Sicong Geng; Jing Wang; Yiting Wang; Zhiqiang Yan; Lei Yu

doi:10.1186/s13045-017-0519-7

Journal of Hematology & Oncology (Aug 2017)

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

Mingxue Fan,
Minghao Li,
Lipeng Gao,
Sicong Geng,
Jing Wang,
Yiting Wang,
Zhiqiang Yan,
Lei Yu

Affiliations

Mingxue Fan: Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University
Minghao Li: Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University
Lipeng Gao: Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University
Sicong Geng: China Novartis Institutes for Biomedical Research Co., Ltd., GDD/TRD/Chemical and Pharmaceutical Profiling
Jing Wang: Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University
Yiting Wang: Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University
Zhiqiang Yan: Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University
Lei Yu: Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University

DOI: https://doi.org/10.1186/s13045-017-0519-7
Journal volume & issue: Vol. 10, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancies, many studies have attempted to translate the success of CAR T cell therapy to other malignancies, including AML. This review summarizes the current advances in CAR T cell therapy against AML, including preclinical studies and clinical trials, and discusses the potential AML-associated surface markers that could be used for further CAR technology. Finally, we describe strategies that might address the current issues of employing CAR T cell therapy in AML.

Published in Journal of Hematology & Oncology

ISSN: 1756-8722 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jhoonline.biomedcentral.com/

About the journal

Abstract

Keywords